The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 26, 2020

Filed:

Nov. 06, 2015
Applicants:

The Regents of the University of Michigan, Ann Arbor, MI (US);

Board of Trustees of Michigan State University, East Lansing, MI (US);

Inventors:

Scott D. Larsen, South Lyon, MI (US);

Richard Neubig, East Lansing, MI (US);

Andrew Haak, Rochester, MN (US);

Kim Hutchings, Dexter, MI (US);

Walajapet Rajeswaran, Canton, MI (US);

Dinesh Khanna, Ann Arbor, MI (US);

Erika Mathes Lisabeth, Howell, MI (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 211/06 (2006.01); C07D 211/60 (2006.01); C07D 417/14 (2006.01); C07D 405/10 (2006.01); C07D 409/10 (2006.01); C07D 405/14 (2006.01); C07D 401/10 (2006.01); C07D 401/06 (2006.01); C07D 417/06 (2006.01); C07D 413/14 (2006.01); C07D 417/10 (2006.01); C07D 413/06 (2006.01); C07D 405/06 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); C07D 211/60 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 405/06 (2013.01); C07D 405/10 (2013.01); C07D 405/14 (2013.01); C07D 409/10 (2013.01); C07D 413/06 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 417/10 (2013.01);
Abstract

Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor ('MRTF/SRF'), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.


Find Patent Forward Citations

Loading…